# ABACAVIR; DOLUTEGRAVIR; LAMIVUDINE
> **NDA217070** · New Drug Application · Sponsor: AUROBINDO PHARMA USA · Approved 2023-08-14
## Drug
- **FDA Application Number:** NDA217070
- **Application type:** New Drug Application
- **Brand name:** ABACAVIR; DOLUTEGRAVIR; LAMIVUDINE
- **Generic name:** Abacavir
- **Active ingredients:** ABACAVIR; DOLUTEGRAVIR; LAMIVUDINE
- **Dosage form:** TABLET
- **Route:** ORAL
- **Marketing status:** None (Tentative Approval)
- **Sponsor:** AUROBINDO PHARMA USA
- **First approval:** 2023-08-14
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217070)
---
*MORVS · CC0 1.0*